United States Cancer Biomarkers Market Outlook
The United States Cancer Biomarkers Market size was valued at USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031 expanding at a CAGR of 11.2% during 2023 – 2031. The growth of the market is attributed to increasing prevalence of cancer and changing lifestyle.
Around 19.3 million people suffer from cancer in the world and in the US, and approximately 1.8 million cases were alone found in 2020. Cancer biomarkers are molecules that show the existing of cancerous cells in the body.
It can be found in the blood, stool, urine, tumor tissue, or other tissues. Various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids are available. These biomarkers are used as diagnostics, prognostics, and surrogate endpoints.
United States Cancer Biomarkers Market Trends, Drivers, Restraints, and Opportunities
- Increasing geriatric population is projected to boost the market growth in the coming years.
- Rising lifestyle disorders and consumption of drugs and alcohol is anticipated to drive the market growth during the forecast period.
- Increasing technological advancements is expected to spur the market growth during the forecast period.
- Growing patient assistance programs is projected to boost the market growth in the coming years.
- A government initiative to control the cancer diseases and policies in favor of the industry is expected to spur the market growth during the forecast period.
- Proving clinical validity and utility of biomarker-based tests can create challenges for the market growth.
- High cost of medicines is estimated to restrict the market growth in the coming years.
- Increasing demand for personalized medicine can create lucrative opportunities during the forecast period.
Scope of United States Cancer Biomarkers Market Report
The report on the United States cancer biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Cancer Biomarkers Market - United States Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Diseases (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer and Others), Types (Protein Biomarkers, Genetic Biomarkers, and Others), and Profiling Technologies (OMICS Technology, Imaging Technology, Immunoassays, and Cytogenetic)
|
|
Country
|
The US
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott Laboratories Inc.; Agilent Technologie; Biomerieux; F. Hoffmann-La Roche Lt; Hologic Inc.; Illumina Inc.; and Thermo Fisher Scientific
|
United States Cancer Biomarkers Market Segment Insights
Breast cancer segment to hold a significant market share
On the basis of diseases, the United States cancer biomarkers market is divided into prostate cancer, breast cancer, lung cancer, colorectal cancer and others. The lung cancer segment is expected to represent a key share of the market in the coming years due to increasing air pollution in the country, which is a major risk factor for lung cancer.
However, the breast cancer segment is anticipated to expand at a rapid pace during the forecast period owing to the adoption of unhealthy lifestyle, genetic profile of patients, growth in female geriatric population, and exposure to harmful radiations.
Protein biomarkers segment is expected to grow at a rapid pace
Based on types, the United States cancer biomarkers market is segregated into protein biomarkers, genetic biomarkers, and others. The genetic biomarkers segment is anticipated to hold a key share of the market in the coming years due to use of advance technologies for mutation detection. On the other hand, the protein biomarkers segment is anticipated to expand at a rapid pace during the forecast period owing to use of targets for therapeutic treatments.
OMICS technology is estimated to hold a major market share
On the basis of profiling technologies, the United States cancer biomarkers market is segregated into OMICS technology, imaging technology, immunoassays, and cytogenetic. The imaging technology segment is expected to represent a key share of the market in the coming years due to its efficiency in early diagnosis of cancer. On the other hand, the OMICS technology segment is anticipated to expand at a rapid pace during the forecast period owing to reduced cost in genome sequencing.
Segments
The United States cancer biomarkers market has been segmented on the basis of
Diseases
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Others
Types
- Protein Biomarkers
- Genetic Biomarkers
- Others
Profiling Technologies
- OMICS Technology
- Imaging Technology
- Immunoassays
- Cytogenetic
Country
Key Players
Competitive Landscape
Key players competing in the United States cancer biomarkers market includes Abbott Laboratories Inc.; Agilent Technologie; Biomerieux; F. Hoffmann-La Roche Lt; Hologic Inc.; Illumina Inc.; and Thermo Fisher Scientific.
Some of these players are engaging in business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market share.
Request For Customization
Enquiry Before Buying
Speak With Analyst
